As of Jun 24
| -0.07 / -5.15%|
The 2 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 4.50, with a high estimate of 6.00 and a low estimate of 3.00. The median estimate represents a +248.84% increase from the last price of 1.29.
The current consensus among 2 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.